Risk-adapted management of thyroid cancer

Endocrine Practice

Volumn 14, Issue 6, 2008, Pages 764-774

  Tuttle, R Michael ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; THYROTROPIN;

CANCER RECURRENCE; CANCER STAGING; CANCER THERAPY; FOLLOW UP; HUMAN; MEDICAL DECISION MAKING; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; THYROID CANCER; THYROID SURGERY; PATHOLOGY; RISK FACTOR; THYROID TUMOR;

HUMANS; RISK FACTORS; RISK MANAGEMENT; THYROID NEOPLASMS;

EID: 64749109230     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.14.6.764     Document Type: Review

References (27)

1. Hundahl SA, Cady B, Cunningham MP, et al (U.S. and German Thyroid Cancer Study Group). Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996: an American College of Surgeons Commission on Cancer patient care evaluation study. Cancer. 2000;89:202-217.
2. Tuttle RM, Leboeuf R. Follow up approaches in thyroid cancer: a risk adapted paradigm. Endocrinol Metab Clin North Am. 2008;37:419-435, ix-x.
3. Tuttle RM, Leboeuf R, Shaha A.Medical management of thyroid cancer: a risk adapted approach. J Surg Oncol. 2008;97:712-716.
4. Mazzaferri EL. Management of low-risk differentiated thyroid cancer. Endocr Pract. 2007;13:498-512.
5. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-1463.
6. Cooper DS, Doherty GM, Haugen BR, et al (American Thyroid Association Guidelines Taskforce). Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109-142.
7. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W (European Thyroid Cancer Taskforce). European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium [published correction appears in Eur J Endocrinol. 2006;155:385]. Eur J Endocrinol. 2006;154:787-803.
8. Shaha AR, Shah JP, Loree TR. Low-risk differentiated thyroid cancer: the need for selective treatment. Ann Surg Oncol. 1997;4:328-333.
9. American Cancer Society, Inc. Cancer Facts and Figures 2006. http://www.cancer.org/docroot/STT/content/STT- 1x-Cancer-Facts--Figures-2006. asp. Accessed for verification August 21, 2008.
10. Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma: a study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer. 1979;15:1033-1041.
11. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947-953.
12. Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control. 2000;7:229-239.
13. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989 [with discussion]. Surgery. 1993;114:1050-1058.
14. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102:1088-1095.
15. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer [published correction appears in Am J Med. 1995;98:215]. Am J Med. 1994;97:418-428.
16. Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid [with discussion]. Surgery. 1995;118:1131-1138.
17. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. V.2.2007. http://www.nccn.org/ professionals/ physician-gls/PDF/thyroid.pdf. Accessed for verification August 21, 2008.
18. Sherman SI, Brierley JD, Sperling M, et al (National Thyroid Cancer Treatment Cooperative Study Registry Group). Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. Cancer. 1998;83:1012-1021.
19. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg. 2007;245:366-378.
20. Ito Y, Higashiyama T, Takamura Y, et al. Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. World J Surg. 2007;31:2085-2091.
21. Welsch M, Abeln M, Zaplatnikov K, et al. Multiparameter scoring system for the prognosis of differentiated thyroid cancer [with quiz]. Nuklearmedizin. 2007;46:257-262, N53-N54.
22. Kim TY, Kim WB, Kim ES, et al. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:1440-1445.
23. Lin JD, Huang MJ, Hsu BR, et al. Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas. J Surg Oncol. 2002;80:45-51.
24. Tuttle RM, Brokhin M, Omry G, et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med. 2008;49:764-770.
25. Baudin E, Travagli JP, Ropers J, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer. 1998;83:553-559.
26. Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98:31-40.
27. Wang W, Larson SM, Tuttle RM, et al. Resistance of [18F]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid. 2001;11:1169-1175.